Topics
High-grade gliomas | Treatment | Chemotherapy | Temozolomide
Home > Publications > Topics > High-grade gliomas > Treatment > Chemotherapy > Temozolomide
*Omene E, Abdel-Rahman O, Batuyong E, Patel S, Coppens R, Easaw J,
Young K.
Switch to generic formulation
of temozolomide results in statistically significant increase in
grade 3 and 4 bone marrow toxicity in glioma patients in the
province of Alberta.
Neurooncol
Pract. 2023 Oct 27;11(2):171-177. doi:
10.1093/nop/npad065. PMID:
38496912. Observational study. ˍ
*Elia A, Roux A, Trancart B, Moiraghi A, Seneca M, Dezamis E,
Varlet P, Chretien F, Oppenheim C, Zanello M, Pallud J.
Watch-and-wait approach versus
adjuvant treatment after radical awake resection in selected
adult-type grade 3 gliomas, isocitrate
dehydrogenase mutant: A
case-matched cohort.
Neurooncol
Adv. 2024 Nov 18;6(1):vdae189. doi:
10.1093/noajnl/vdae189. PMID: 39620200.
Observational study. ˍ
Ding X, Chen D, Zhang Z, Qi Y, Chen D, Wen J, Wang Y, Cheng H, Ji
C, Chen L, Tang C, Yao Y.
Cisplatin
and Alternating Temozolomide in Recurrent High-Grade Gliomas:
Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase
II Clinical Trial.
Clin
Med Insights Oncol. 2025 Jul 13;19:11795549251350188.
doi:
10.1177/11795549251350188. PMID:
40661859. Interventional study.
ˍ
ClinicalTrials.gov
ID: NCT02263105.